BCLSI
PTGX icon

Bain Capital Life Sciences Investors’s Protagonist Therapeutics PTGX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,364,410
Closed -$25.8M – 36
2022
Q4 		$25.8M Buy
2,364,410
+103,838
+5% +$876K 2.88% 11
2022
Q3 		$19.1M Hold
2,260,572
– – 2.27% 16
2022
Q2 		$17.9M Buy
+2,260,572
New +$27.3M 2.1% 14

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bain Capital Life Sciences Investors's PTGX Position: Q1 2023 in Review

Bain Capital Life Sciences Investors sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 2,364,410 shares — an estimated $25.8M sold.

Bain Capital Life Sciences Investors first reported a position in PTGX in Q2 2022 and held it in 3 quarters. The position peaked at $25.8M in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Bain Capital Life Sciences Investors reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 2,364,410 Protagonist Therapeutics shares in Q1 2023, an estimated $25.8M.
  • Bain Capital Life Sciences Investors first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 3 quarters.
  • Bain Capital Life Sciences Investors's Protagonist Therapeutics position peaked at $25.8M in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2023, filed 15 May 2023.